Lily Agrawal1, Nasrin Azad2, Gideon D Bahn3, Ling Ge3, Peter D Reaven4, Rodney A Hayward5, Domenic J Reda3, Nicholas V Emanuele2. 1. Medical Service, Endocrinology Section, Edward Hines Jr. VA Hospital, 5000 S. 5th Avenue, Building 1, (Mail code 111), Hines, IL, 60141, USA. Lily.agrawal@va.gov. 2. Medical Service, Endocrinology Section, Edward Hines Jr. VA Hospital, 5000 S. 5th Avenue, Building 1, (Mail code 111), Hines, IL, 60141, USA. 3. Cooperative Studies Program Coordinating Center, Hines, IL, USA. 4. Carl T. Hayden VA Medical Center, Phoenix, AZ, USA. 5. VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Abstract
AIMS/HYPOTHESIS: We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. METHODS:VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. RESULTS: By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min-1 1.73 m-2 (OR 1.34 [95% CI 1.05, 1.71], p = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p = 0.03) or high risk (RR 2.3, p = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA1c, blood pressure or lipid levels. CONCLUSIONS/ INTERPRETATION: After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min-1 1.73 m-2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
RCT Entities:
AIMS/HYPOTHESIS: We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. METHODS:VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. RESULTS: By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min-1 1.73 m-2 (OR 1.34 [95% CI 1.05, 1.71], p = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p = 0.03) or high risk (RR 2.3, p = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA1c, blood pressure or lipid levels. CONCLUSIONS/ INTERPRETATION: After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min-1 1.73 m-2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
Entities:
Keywords:
Intensive glycaemic control; Nephropathy; Renal outcomes; Type 2 diabetes
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Rodney A Hayward; Peter D Reaven; Wyndy L Wiitala; Gideon D Bahn; Domenic J Reda; Ling Ge; Madeline McCarren; William C Duckworth; Nicholas V Emanuele Journal: N Engl J Med Date: 2015-06-04 Impact factor: 91.245
Authors: Sophia Zoungas; Hisatomi Arima; Hertzel C Gerstein; Rury R Holman; Mark Woodward; Peter Reaven; Rodney A Hayward; Timothy Craven; Ruth L Coleman; John Chalmers Journal: Lancet Diabetes Endocrinol Date: 2017-03-30 Impact factor: 32.069
Authors: William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang Journal: N Engl J Med Date: 2008-12-17 Impact factor: 91.245
Authors: Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri Journal: Diabetes Res Clin Pract Date: 1995-05 Impact factor: 5.602
Authors: Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas Journal: Kidney Int Date: 2013-01-09 Impact factor: 10.612
Authors: Lily Agrawal; Nasrin Azad; Nicholas V Emanuele; Gideon D Bahn; Derrick G Kaufman; Thomas E Moritz; William C Duckworth; Carlos Abraira Journal: Diabetes Care Date: 2011-07-20 Impact factor: 19.112
Authors: Monika Lechleitner; Martin Clodi; Heidemarie Abrahamian; Helmut Brath; Johanna Brix; Heinz Drexel; Peter Fasching; Bernhard Föger; Claudia Francesconi; Elke Fröhlich-Reiterer; Jürgen Harreiter; Sabine E Hofer; Friedrich Hoppichler; Joakim Huber; Susanne Kaser; Alexandra Kautzky-Willer; Bernhard Ludvik; Anton Luger; Julia K Mader; Bernhard Paulweber; Thomas Pieber; Rudolf Prager; Birgit Rami-Merhar; Michael Resl; Michaela Riedl; Michael Roden; Christoph H Saely; Christian Schelkshorn; Guntram Schernthaner; Harald Sourij; Lars Stechemesser; Harald Stingl; Hermann Toplak; Thomas C Wascher; Raimund Weitgasser; Yvonne Winhofer-Stöckl; Sandra Zlamal-Fortunat Journal: Wien Klin Wochenschr Date: 2019-05 Impact factor: 1.704
Authors: Derek LeRoith; Geert Jan Biessels; Susan S Braithwaite; Felipe F Casanueva; Boris Draznin; Jeffrey B Halter; Irl B Hirsch; Marie E McDonnell; Mark E Molitch; M Hassan Murad; Alan J Sinclair Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse Journal: Diabetologia Date: 2022-09-24 Impact factor: 10.460
Authors: Amy K Mottl; John B Buse; Faramarz Ismail-Beigi; Ronald J Sigal; Carolyn F Pedley; Vasilios Papademetriou; Debra L Simmons; Lois Katz; Josyf C Mychaleckyj; Timothy E Craven Journal: Clin J Am Soc Nephrol Date: 2018-10-25 Impact factor: 8.237